SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amid mixed community sentiment, with some expressing frustration over its price performance compared to Bitcoin and other altcoins.  Discussions also involve comparisons to Keeta, highlighting Cardano's methodical approach versus Keeta's focus on high-speed, compliant infrastructure; the potential launch of Midnight token, and speculation around an ADA ETF.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach all-time highs, fueled by speculation around potential Fed rate cuts and renewed interest in precious metals as a hedge against economic uncertainty. Community members are discussing technical breakouts, potential for a silver squeeze, and historical inflation-adjusted valuations, while some express concerns about market manipulation and potential pullbacks. The broader context involves increased industrial demand for silver and its role as a safe-haven asset amid global economic concerns.

Columbus Circle Capital Corp. I operates as a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which refer to throughout this prospectus as initial business combination. The company was founded in June 2024 and is headquartered in New York, NY.

Columbus Circle Capital Corp I - Ordinary Shares - Class A

BRR is trending as chatter swirls around its upcoming merger vote and potential exposure to Bitcoin, with some highlighting the involvement of Eric Jackson and Anthony Pompliano. The community is speculating on a potential short squeeze and the impact of amendments to the deal, with excitement building for a possible rally.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending amid speculation around potential bids from Comcast, Netflix and Paramount, with some community members discussing the likelihood of a deal being reached by the end of the year. Community members are debating the potential bid prices and who might win the bidding war, with many speculating on potential offers from other major players. Some traders are taking bullish positions, while others express skepticism about management and debt.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending due to its partnership with Aquanow to expand stablecoin (USDC) payments in Central and Eastern Europe, the Middle East, and Africa, which the community sees as a move to strengthen its blockchain-based cross-border capabilities.  Community members are also discussing option activity and technical analysis, while others debate whether it is overvalued compared to Mastercard. Some traders are also watching for a potential breakout with various price targets being mentioned.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is trending as the community discusses unusual options activity and potential catalysts, including a possible lidar deal. The stock's momentum and recent 52-week highs are balanced against concerns about potential pullbacks and changing EV strategies. Traders are also monitoring the broader automotive sector and macroeconomic factors influencing GM's performance.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM is trending as community members highlight its strong financials and pipeline, especially Auvelity's potential in treating Alzheimer's agitation. Recent analyst upgrades and positive trial data are fueling optimism, though some caution against over-reliance on pipeline developments. Discussions also include potential buyout scenarios and the impact of regulatory decisions on the stock's future.

BlackRock Institutional Trust Company N.A. - iShares Biotechnology ETF

iShares Biotechnology ETF

IBB is trending as traders discuss AI's impact on biotech, potential M&A activity, and revenue multiples compared to peers. Community members are weighing in on potential upside, technical analysis, and individual stock performance within the biotech sector. Recent news about Centers for Medicare & Medicaid Services (CMS) price cuts may also be impacting the ETF.

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Valneva is trending due to positive Phase 2 booster results for its Lyme disease vaccine, developed in partnership with Pfizer, fueling speculation about a potential buyout. The community is focused on the significant revenue potential of the Lyme vaccine and anticipating Phase 3 trial data. Some investors express caution, referencing past setbacks, while others see the current low trading volume as an opportunity for exponential gains upon positive news.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

QQQI is trending as investors discuss its high dividend yield and tax advantages, particularly Return of Capital (ROC), making it attractive for taxable accounts. Community members are weighing QQQI against alternatives like JEPQ, focusing on long-term income generation and NAV stability. Some are considering QQQI for retirement income, emphasizing its predictable monthly payouts amidst market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Research Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Lexeo Therapeutics in a report...

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 1,127 shares of the company's stock in a transaction that occurred on Tuesday, November 18th. The stock was...

Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Lexeo Therapeutics in a research report on Thursday. They set an "overweight" rating and a $19.00 price target for the company...

Equities Analysts Set Expectations for LXEO FY2025 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Lexeo Therapeutics in a note issued to investors on...

Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's  What You Should Know

The consensus price target hints at a 124.3% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Equities researchers at Leerink Partnrs increased their FY2025 earnings per share estimates for shares of Lexeo Therapeutics in a report...

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by...

Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday...

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?

The consensus price target hints at a 108.2% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Current Price	$9.86
Prev Close	$9.63
Open	$9.71
Dividend Yield	0.00%
50-Day Moving Average	$8.39
Beta	1.93
Avg. Volume	1.46M
PE Ratio	-3.65

52-Week High	$10.38
52-Week Low	$1.45
Market Capitalization	$703.13M
EPS (Annual)	-$3.09
Price to Book	4.48
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LXEO News

LXEOLexeo Therapeutics Inc.